← Eichor
Condition: Locally Advanced Soft Tissue Sarcoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Locally Advanced Soft Tissue Sarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatm
NA · 11 location(s) · Centre Oscar Lambret · NCT06211257Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831Vebreltinib for Advanced or Metastatic CCS
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07153887Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With
Phase 1/Phase 2 · 10 location(s) · Anocca AB · NCT07145450A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Lamassu Bio Inc · NCT06578624Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Phase 2 · 22 location(s) · UNICANCER · NCT06333314Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
Phase 2 · 17 location(s) · Italian Sarcoma Group · NCT04383119A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung C
Phase 3 · 225 location(s) · Merck Sharp & Dohme LLC · NCT06345729Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcom
Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT05019703I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase 2 · 42 location(s) · QuantumLeap Healthcare Collaborative · NCT01042379Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Phase 1/Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT04577014A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06066138Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT)
NA · 1 location(s) · Azienda Ospedaliero-Universitaria Careggi · NCT05761054A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Phase 1 · 6 location(s) · Angiex, Inc. · NCT06440005Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06176989Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid M
Phase 1 · 2 location(s) · Zelluna Immunotherapy AS · NCT07613723A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/Phase 2 · 68 location(s) · Turning Point Therapeutics, Inc. · NCT04094610EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410676A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Kivu Bioscience Inc. · NCT07229313A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04332874Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Gra
Phase 2 · 22 location(s) · Centre Leon Berard · NCT03624244A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Phase 1 · 9 location(s) · Avacta Life Sciences Ltd · NCT04969835Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Phase 1 · 36 location(s) · Inhibrx Biosciences, Inc · NCT03715933Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.